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Abstract. Treatment failure in metastatic bladder cancer is 
commonly caused by acquisition of resistance to chemotherapy 
in association with tumor progression. Since alterations of LQWHJULQVFDQLQÁXHQFHWKHDGKHVLYHDQGLQYDVLYHEHKDYLRUVRI
urothelial bladder cancer cell lines, the present study aimed WRHYDOXDWHWKHUROHRILQWHJULQVLQEODGGHUFDQFHUFHOOVZLWKDFTXLUHGUHVLVWDQFHWRVWDQGDUGÀUVWOLQHFKHPRWKHUDS\ZLWK
gemcitabine, and cisplatin. Therefore, four gemcitabine- 
and four cisplatin-resistant sublines out of a panel of four 
parental urothelial bladder cancer cell lines (TCC-SUP, 
HT1376, T24, and 5637) were used. Expression of integrin 
subunits Ơ3, Ơ5, Ơ6, ơ1, ơ3, and ơZDVGHWHFWHGXVLQJÁRZ
cytometry. Adhesion and chemotaxis were analyzed. For 
functional assays, integrin ơ1 was attenuated with a blocking 
antibody. In untreated cells, chemotaxis was upregulated in 
3/4 gemcitabine-resistant sublines. In cisplatin-resistant cells, 
chemotaxis was enhanced in 2/4 cell lines. Acquired chemo-
resistance induced the upregulation of integrin ơ1 in all four 
tested gemcitabine-resistant sublines, as well as an upregula-
tion in 3/4 cisplatin-resistant sublines compared with parental 
cell lines. Following the inhibition of integrin ơ1, adhesion 
to extracellular matrix components was downregulated in 
3/4 gemcitabine-resistant sublines and in all four tested 
cisplatin-resistant sublines. Since integrin ơ1 is frequently 
upregulated in chemoresistant urothelial cancer cell lines 
and inhibition of integrin ơPD\LQÁXHQFHDGKHVLRQIXUWKHUVWXGLHVDUHZDUUDQWHGWRHYDOXDWHLQWHJULQơ1 as a potential 
therapeutic target for bladder cancer in vivo.
Introduction
Urothelial cancer of the bladder is the 4th most commonly 
diagnosed cancer in men worldwide (1). Patients with metastatic 
disease are often treated with a combination chemotherapy 
containing gemcitabine and cisplatin as a standard of care (2,3). +RZHYHUWKHWUHDWPHQWVXFFHVVLVOLPLWHGUHVXOWLQJLQDPHGLDQVXUYLYDORIPRQWKV7UHDWPHQWIDLOXUHLVFRPPRQO\FDXVHG
by acquired resistance after primary response (2,3). Therefore, HIÀFLHQWVHFRQGOLQHFKHPRWKHUDSLHVDUHXUJHQWO\QHHGHG,QWHJULQVKDYHEHHQLGHQWLÀHGWRSOD\DQLPSRUWDQWUROHLQWKHGHYHORSPHQWRIUHVLVWDQFHWRFKHPRWKHUDS\LQEODGGHU
cancer (4). These molecules are transmembrane receptors 
with two different chains, an Ơ (alpha) and a ơ (beta) subunit. 
Integrins are bridges for cell-cell and cell-extracellular matrix 
(ECM) interactions. Cell-matrix contact plays a fundamental 
role in the metastatic potential of tumors (5). Alterations RI LQWHJULQH[SUHVVLRQPD\UHVXOW LQDQHQKDQFHGDGKHVLYHEHKDYLRU LQ EODGGHU FDQFHU 6 0RUHRYHU WKH H[SUHVVLRQ
patterns of integrin subtypes are known to be important 
mediators of tumor cell de-differentiation and tumor prolif-
eration (7). Furthermore, it was shown that integrins were LQYROYHGLQWKHGHYHORSPHQWRIPHWDVWDVLVDQGUHFXUUHQFHRI
urothelial cancer (6,8,9).'UXJDGDSWHGFDQFHUFHOO OLQHVKDYHEHHQ VXFFHVVIXOO\
used to study cancer cell resistance mechanisms (10,11). To UHÁHFWWKHKHWHURJHQHLW\RILQGLYLGXDOEODGGHUFDQFHUSDWLHQWVDQGWRHQDEOHDV\VWHPDWLFHYDOXDWLRQRIWKHUROHRILQWHJULQV
concerning resistance acquisition, we used a panel of 12 
urothelial cancer cell lines consisting of 4 parental chemosen-VLWLYHFHOOOLQHVDQGWKHLUVXEOLQHVZLWKDFTXLUHGUHVLVWDQFHWR
gemcitabine or cisplatin (12,13).
Materials and methods
Drugs. Cisplatin was purchased from Gry-Pharma (Kirchzarten, 
Germany), gemcitabine from Lilly (Bad Homburg, Germany).
Cell lines. The cell lines 5637, T24, HT1376, and TCC-SUP 
were obtained from the American Type Culture Collection 
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(Manassas, VA, USA). The following drug-resistant sublines 
were established by continuous exposure to increasing drug FRQFHQWUDWLRQVDVGHVFULEHGSUHYLRXVO\12,14) and are part of 
the Resistant Cancer Cell Line (RCCL) collection (www.kent 
.ac.uk/stms/cmp/RCCL/RCCLabout.html): 5637rCDDP1000 
(cisplatin-resistant, 1,000 ng cisplatin/ml), 5637rGEMCI20 
(gemcitabine-resistant, 20 ng gemcitabine/ml), T24rCDDP1000, 
T24 rGEMCI20, HT1376 rCDDP1000, HT1376 rGEMCI20, 
TCC-SUPrCDDP1000, and TCC-SUPrGEMCI20. All cell lines ZHUHJURZQLQ,VFRYH
VPRGLÀHG'XOEHFFR
VPHGLXPVXSSOH-
mented with 10% fetal calf serum (FCS; Gibco, Karlsruhe, 
Germany), 100 IU/ml penicillin, and 100 µg/ml streptomycin DW Ý& &HOO OLQH DXWKHQWLFDWLRQ ZDV SHUIRUPHG E\ VKRUWWDQGHPUHSHDWSURÀOLQJ
Cell adhesion to extracellular matrix components. 24-well 
plates were coated with extracellular matrix components 0DWULJHO&RUQLQJ$PVWHUGDP7KH1HWKHUODQGVRYHUQLJKW
Plates were washed with 1% ERYLQHVHUXPDOEXPLQBSA) 
in phosphate buffered saline (3%6WREORFNQRQVSHFLÀFFHOO
adhesion. Thereafter, 0.5x106 tumor cells were added to each 
well for 60 min. Subsequently, non-adherent tumor cells were ZDVKHGRII7KHDGKHUHQWFHOOVZHUHÀ[HGZLWKJOXWDUDOGH-K\GHDQGFRXQWHGLQÀYHGLIIHUHQWÀHOGVXVLQJDPLFURVFRSH[REMHFWLYHWRFDOFXODWHWKHPHDQFHOOXODUDGKHVLRQUDWH
Chemotaxis. Serum induced cell migration was examined using 
6-well transwell chambers (Greiner, Frickenhausen, Germany) ZLWKPSRUHV7RHYDOXDWHFHOOPLJUDWLRQFHOOVZHUHSODFHG
in the upper chamber for 20 h in serum-free medium. The lower 
chamber contained 10% serum. After incubation, the upper 
surface of the transwell membrane was wiped gently with a FRWWRQVZDEWRUHPRYHQRQPLJUDWLQJFHOOV&HOOVPLJUDWLQJWR
the lower surface of the membrane were stained using hema-
toxylin and counted. Cells migrating into the lower chamber 
were counted separately under the microscope.
Blocking study. Cells were preincubated for 60 min with a func-
tion-blocking anti-integrin ơ1 monoclonal antibody (20 mg/l) 
(MAB 2253Z; MerckMillipore, Darmstadt, Germany). 
Controls remained untreated. Adhesion and chemotaxis was WHVWHGDVLQGLFDWHGDERYH
Flow cytometry. Cells were washed in blocking solution (PBS, %6$DQGWKHQLQFXEDWHGIRUPLQDWÝ&ZLWKSK\FRHU-
ythrin (PE)-conjugated monoclonal antibodies directed against 
the following integrin subtypes: Anti-Ơ3 (IgG1; clone C3II.1), 
anti-Ơ5 (IgG1; clone IIA1), anti-Ơ6 (IgG2b, clone MP 4F10), 
anti-ơ1 (IgG1; clone MAR4), anti-ơ3 (IgG1; clone VI-PL2) or 
anti-ơ4 (IgG2a; clone 439-9B; all: BD Biosciences, Heidelberg, *HUPDQ\,QWHJULQH[SUHVVLRQZDVPHDVXUHGE\ÁRZF\WRP-
etry (FACSCalibur; BD Biosciences, Heidelberg, Germany). 
Mouse IgG1-PE (MOPC-21) or mouse IgG2a-PE (G155-178; 
all: BD Biosciences) antibodies were used as isotype control.
Immunohistochemistry. FDVHVRILQYDVLYHDQGQRQLQYDVLYH
bladder cancers as well es corresponding normal urothelium ZHUHWDNHQIURPWKHDUFKLYHRIWKH'U6HQFNHQEHUJ,QVWLWXWH
of Pathology in Frankfurt. Tissue sections were stained for 
Integrin ơ1, (D2E5) Rabbit mAb, Cell Signaling Technology 
(Waltham, MA, USA), dilution 1:100. In brief, 4 µm sections 
were cut and pretreated with Trilogy, Cell Marcque 
(Rocklin, CA, USA), incubated with the antibody, antigen UHWULHYDOZDVSHUIRUPHGDWS+LQDPLFURZDYHRYHQXVLQJWKH
Peroxidase-FLEX EnVision kit (Dako, Jena, Germany).
A pathologist, who was blinded to clinical history and 
therapeutic response, scored the immunohistochemical VWDLQLQJXVLQJDÀYHVWDJHVWDLQLQJVFRUH QHJDWLYH ZHDN PRGHUDWH VWURQJ YHU\VWURQJ
Images were acquired using a digital slide scanner 
(ScanScope XT; Aperio, Vista, CA, USA).
Statistical analysis. Results are expressed as mean ± SD 
of at least three independent experiments. For statistical DQDO\VLVVWXGHQW
VWWHVWDQDO\VLVRIYDULDQFH$129$DQG6WXGHQW1HZPDQ.HXOV7HVW ZHUH SHUIRUPHG ZKHQHYHU
applicable. P<0.05 was considered to indicate a statistically VLJQLÀFDQWGLIIHUHQFH
Results
Influence of acquired resistance on adhesion to extracel-
lular matrix components. In untreated cells, adhesion to 
extracellular matrix components was decreased in 2 of 
4 gemcitabine-resistant sublines (HT1376rGEMCI20 and 
TCC-SUPrGEMCI20) and upregulated in 2 of 4 cell lines 
(T24rGEMCI20 and 5637rGEMCI20) compared to parental 
cells. In cisplatin-resistant sublines, adhesion was decreased 
in 1 of 4 cisplatin-resistant sublines (TCC-SUPrCDDP1000) 
and enhanced in 2 cell lines (HT1376rCDDP1000 and 
5637rCDDP1000) (Fig. 1).
Influence of acquired chemoresistance on chemotaxis. 
Chemotaxis was enhanced in 3 of 4 gemcitabine-resistant 
urothelial cancer cell lines (gemcitabine-resistant sublines 
of TCC-SUP, HT1376 and T24). In cisplatin-resistant 
sublines, chemotaxis was enhanced in HT1376rCDDP1000 and 
T24rCDDP1000 compared to parental cell lines (Fig. 2).
Differential expression of cell surface integrins. Expression RILQWHJULQVRQWKHFHOOVXUIDFHZDVDQDO\]HGE\ÁRZF\WRP-
etry (Fig. 3). In gemcitabine-resistant sublines, the expression 
of integrin Ơ3 was enhanced in 3 sublines (gemcitabine-resis-
tant sublines of T24, 5637, and TCC-SUP) and diminished in 
HT1376rGEMCI20 compared to parental cell lines. Integrin ơ1 expression was upregulated in all gemcitabine-resistant 
sublines compared to parental cells. Integrin ơ4 expression 
was enhanced in TCC-SUPrGEMCI20 and diminished in 
T24rGEMCI20 and in 5637rGEMCI20.
Comparing cisplatin-resistant cell lines, Integrin Ơ3 
expression was upregulated in 3 of 4 sublines (cisplatin-resis-
tant sublines of T24, 5637, and TCC-SUP) and downregulated 
in HT1376rCDDP1000. Integrin Ơ5 was upregulated in 3 of 4 
sublines (cisplatin-resistant sublines of 5637, TCC-SUP, and 
HT1376). Integrin ơ1 expression was upregulated in 3 of 4 
sublines (cisplatin-resistant sublines of HT1376, T24, and 
5637) and downregulated in TCC-SUPrCDDP1000. Integrin ơ4 
was upregulated in HT1376rCDDP1000 and downregulated in 
all other tested sublines (cisplatin-resistant sublines of T24, 
5637, and TCC-SUP).
ONCOLOGY LETTERS  14:  5513-5518,  2017 5515
Immunohistochemical staining of integrin ơ1. In non-malig-
nant tissue samples, integrin ơZDVRQO\YLVLEOHLQWKHEDVDO
layer of the urothelium. The medium staining score for normal 
urothelium was between QHJDWLYH to weak (0.88±0.33). In 
bladder cancer samples, the mean integrin ơ1 staining score 
was between moderate and strong (2.48±1.42). There was QRVLJQLÀFDQWGLIIHUHQFHRILQWHJULQơ1 staining between low 
JUDGHWXPRUVRUKLJKJUDGHWXPRUVDQGQRVLJQLÀFDQWGLIIHU-HQFHEHWZHHQQRQPXVFOHLQYDVLYHWXPRUVDQGPXVFOHLQYDVLYH
tumors (Fig. 4).
,QÁXHQFHRIEORFNLQJLQWHJULQơ1 on adhesion and chemotaxis. 
Functional blocking of integrin ơ1 resulted in a reduced adhe-
sion in 2 of 4 parental urothelial cancer cell lines (HT1376 
and T24). In gemcitabine-resistant cells, adhesion was down-
regulated in 3 of 4 cell lines (gemcitabine-resistant sublines 
of HT1376, T24 and TCC-SUP). In cisplatin-resistant cells, 
adhesion was downregulated in all 4 tested cell lines (Fig. 5). :HFRXOGQRWGHWHFWDQLQÁXHQFHRQFKHPRWD[LVDIWHUEORFNLQJ
integrin ơ1 (Fig. 6).
Discussion
In the present study, we used a well-established panel of urothe-
lial cancer cell lines with acquired resistance to gemcitabine 
or cisplatin, the standard therapeutics for metastatic urothelial 
cancer of the bladder (2,3). Cell line panels seem to be neces-VDU\WRUHÁHFWWKHKHWHURJHQHLW\RIGLIIHUHQWSDWLHQWGHULYHG
cancer cell lines. Although the complex scenario of metastatic FRORQL]DWLRQLVQRWIXOO\XQGHUVWRRGWKHUHLVVWURQJHYLGHQFH
that alterations of tumor-matrix contact are necessary to allow 
motile crawling into the surrounding tissue (15).,QVHYHUDOFDQFHUFHOOVUHVLVWDQFHWRJHPFLWDELQHVHHPVWR
be connected with integrins and associated proteins (16-18). 
In addition, resistance to cytotoxic drugs and prolifera-
tion regulation was shown to be dependent on extracellular 
matrix proteins (19). In this study, acquisition of resistance to JHPFLWDELQHRUFLVSODWLQVKRZHGDFKDQJHGDGKHVLYHEHKDYLRUZLWKVRPHUHVLVWDQWVXEOLQHVVKRZLQJDQHQKDQFHGDGKHVLYHEHKDYLRU DQG RWKHU UHVLVWDQW VXEOLQHV EHLQJ OHVV DGKHVLYH
(Fig. 1,QFRQWUDVWWKHLQÁXHQFHRQFKHPRWD[LVZDVPRUH
uniform, with 5 of 8 sublines showing an enhanced chemotaxis DQGQRVXEOLQHZLWKDVLJQLÀFDQWO\GLPLQLVKHGFKHPRWD[LV
after acquisition of resistance (Fig. 2). This is in line with 
Ploenes et al who reported about an enhanced chemotaxis in 
lung cancer cell lines with an increased chemoresistance (20).6LQFHLQWHJULQVVHHPWREHLQYROYHGLQWKHGHYHORSPHQW
of resistance to chemotherapy in bladder cancer (4) and DOWHUDWLRQVRILQWHJULQH[SUHVVLRQFKDQJHDGKHVLYHDQGLQYDVLYHEHKDYLRURIEODGGHUFDQFHUFHOOV6), we aimed to elucidate the 
role of integrins in this context.
Integrin ƠPLJKWEHLQYROYHGLQUHVLVWDQFHDFTXLVLWLRQ
since it was upregulated in 3 of 4 gemcitabine-resistant and 
also in 3 of 4 cisplatin-resistant sublines in this study (Fig. 3). 
Litynska et al (21) tried to analyze the role of integrin Ơ3 in 
bladder cancer by blocking its function. They described that 
adhesion was up- or downregulated after blocking integrin Ơ3 GHSHQGLQJRQWKHWHVWHGFHOOOLQH7KHFHOOOLQHVSHFLÀFHIIHFWV
that can be triggered after acquisition of resistance show the 
heterogeneity between independent cell lines and underline 
the importance of using a panel of cell lines for a better inter-
pretation.
It was reported that integrin Ơ5 contributes to a more 
malignant phenotype in urothelial bladder cancer (22). In our VWXG\WKLVLQWHJULQVXEXQLWZDVRYHUH[SUHVVHGLQPRVWRIWKH
tested chemoresistant sublines what might underline the more 
malignant phenotype of the chemoresistant sublines (Fig. 3).
)LJXUH(YDOXDWLRQRIFHOODGKHVLRQ&RPSDULVRQRIDGKHVLYHEHKDYLRU
of parental bladder cancer cell lines as well as of their gemcitabine- and 
cisplatin-resistant sublines. The plates were coated with extracellular matrix FRPSRQHQWVRYHUQLJKW3ODWHVZHUHZDVKHGZLWK%6$LQ3%6WREORFNQRQVSHFLÀFFHOODGKHVLRQ7KHUHDIWHU[6 tumor cells were added to each 
well for 60 min. Subsequently, non-adherent tumor cells were washed off. 7KHDGKHUHQWFHOOVZHUHÀ[HGZLWKJOXWDUDOGHK\GHDQGFRXQWHGLQÀYHGLIIHUHQWÀHOGVXVLQJDPLFURVFRSH[REMHFWLYHWRFDOFXODWHWKHPHDQ
cellular adhesion rate. Adhesion of parental cell lines was set as 100%. 
*3YVFRQWUROV
)LJXUH(YDOXDWLRQRIFKHPRWD[LV6HUXPLQGXFHGFKHPRWDFWLFPRYHPHQW
was examined using six-well transwell chambers with 8-µm pores. A total of 
0.5x106 tumor cells per ml were placed in the upper chamber in serum-free 
medium. The lower chamber contained 10% serum. After 20 h incubation, 
the upper surface of the transwell membrane was gently wiped with a cotton VZDEWRUHPRYHQRQPLJUDWLQJFHOOV&HOOVZKLFKKDGPRYHGWRWKHORZHU
surface of the membrane were stained using haematoxylin and counted with DPLFURVFRSH[REMHFWLYH7KHPHDQFKHPRWD[LVUDWHZDVFDOFXODWHGIURPÀYHGLIIHUHQWÀHOGV&KHPRWD[LVRISDUHQWDOFHOOOLQHVZDVVHWDV
*3YVFRQWUROV
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:HREVHUYHGWKDWPRVWFKHPRUHVLVWDQWVXEOLQHVVKRZHG
a diminished expression of integrin ơ4 compared to their 
parental counterparts (Fig. 3). Therefore, a downregulation 
of integrin ơ4 could be connected with a more malignant EHKDYLRU7KLVLVLQOLQHZLWKUHSRUWVWKDWDQRYHUH[SUHVVLRQ
of integrin ơ4 inhibits growth and migration in bladder cancer 
cell lines and plays an anti-tumoral role (23,24).
In all gemcitabine-resistant and in 3 of 4 cisplatin-resistant 
sublines, surface expressed integrin ơ1 was upregulated 
compared to parental cell lines (Fig. 3). Since chemotaxis 
was frequently enhanced after acquisition of resistance, these 
results might support the conclusions of Chakraborty et al (25) 
who postulated that blockade of ơLQWHJULQZLWKDVSHFLÀF
antibody could result in alteration of multiple signaling 
pathways related to adhesion and migration. Interestingly, =KDQJDQGFRZRUNHUVVKRZHGWKDWWKH\FRXOGUHYHUVHFKHPR-
resistance to mitomycin c by blocking integrin ơ1 (4). Integrin ơZDVRYHUH[SUHVVHGLQPRVWRI WKHWHVWHGVXEOLQHVDQGLW
was reported to contribute to a more malignant phenotype 
in urothelial bladder cancer (4,25:HFRXOGFRQÀUPLQWKLVVWXG\WKDWRYHUH[SUHVVLRQRILQWHJULQơ1 is associated with a 
malignant phenotype since we detected a stronger expression 
in malignant tissue samples compared to normal urothelium. 1HYHUWKHOHVVWKHUHZDVQRGLIIHUHQWH[SUHVVLRQFRPSDULQJORZ
)LJXUH)ORZF\WRPHWU\DQDO\VLVRILQWHJULQVXUIDFHH[SUHVVLRQ&HOOVZHUHZDVKHGLQEORFNLQJVROXWLRQDQGVWDLQHGZLWKVSHFLÀFPRQRFORQDODQWLERGLHVDV
listed in materials and methods. Mouse IgG1-PE or mouse IgG2a-PE antibodies were used as isotype controls. Fluorescence was analyzed using a FACScan ÁRZF\WRPHWHU7KHUHODWLYHÁXRUHVFHQFHXQLWYDOXHVDUHJLYHQLQSHUFHQWDJHGLIIHUHQFHWRWKHSDUHQWDOFHOOOLQHV3DUHQWDOFHOOOLQHVZHUHVHWDV2QHRI
three independent experiments is shown here. *3YVFRQWUROV
Figure 4. Expression of integrin ơLQQRQPDOLJQDQWXURWKHOLXPDQGXURWKHOLDOFDQFHU$1RUPDOXURWKHOLXPVKRZHGDQHJDWLYHRUDZHDNH[SUHVVLRQRI
intergrin ơ1 only in the basal cell layer. A higher integrin ơH[SUHVVLRQZDVYLVLEOHLQVDPSOHVRI%QRQLQYDVLYHORZJUDGHXURWKHOLDOFDQFHU&QRQLQYDVLYHKLJKJUDGHFDQFHUDQG'PXVFOHLQYDVLYHKLJKJUDGHFDQFHU,PPXQRVWDLQLQJRIUHSUHVHQWDWLYHWLVVXHVDPSOHV
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JUDGHZLWKKLJKJUDGHWXPRUVRUEHWZHHQQRQPXVFOHLQYDVLYHEODGGHUFDQFHUDQGPXVFOHLQYDVLYHEODGGHUFDQFHUFig. 4).
To further analyze the role of integrin ơ1, we suppressed the 
function of integrin ơ1 and meassured adhesion and chemo-WD[LVDIWHUZDUGV7KHUHZDVDQLQÁXHQFHRQDGKHVLRQDIWHU
blocking integrin ơ1 with a reduced adhesion in 2 of 4 parental 
and 3 of 4 gemcitabine-resistant sublines. In cisplatin-resistant 
FHOOVDGKHVLRQZDVHYHQGRZQUHJXODWHGLQDOOWHVWHGFHOO
lines (Fig. 5).
We could not show an influence on chemotaxis after 
blocking integrin ơ1 (Fig. 6,IWKHUHLVQRLQÁXHQFHRQFKHPR-
taxis or if the used transwell migration assay is not able to UHÁHFWWKHLPSDFWRQFKHPRWD[LVLVQRWFOHDU$QH[SODQDWLRQIRUWKHODWWHUPLJKWEHWKDWHIIHFWVWKDWLQÁXHQFHLQYDVLRQDIWHU
)LJXUH,QÁXHQFHRQFKHPRWD[LVDIWHUEORFNLQJLQWHJULQơ1. Bladder cancer cell lines were preincubated for 60 min with a monoclonal anti-integrin ơ1 
blocking antibody (20 mg/l). Controls remained untreated. Cells were then subjected to the chemotaxis assay as indicated. Untreated parental cells were set 
as 100%. *3YVFRQWUROV
)LJXUH,QÁXHQFHRQDGKHVLRQDIWHUEORFNLQJLQWHJULQơ1. Bladder cancer cell lines were preincubated for 60 min with a monoclonal anti-integrin ơ1 blocking 
antibody (20 mg/l). Controls remained untreated. Cells were then subjected to the adhesion assay as indicated. Untreated parental cells were set as 100%. 
*3YVFRQWUROV
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blocking integrin ơ1 are delayed and therefore not detectable 
with the used transwell migration assay.'LVFXVVLQJWKHUROHRIGLIIHUHQWLQWHJULQVDQGWKHLQÁXHQFHRQDGKHVLYHDQGLQYDVLYHEHKDYLRUZHVKRXOGEHDZDUHWKDWGLIIHUHQWLDOO\JXLGHGDGKHVLYHEHKDYLRURIGLIIHUHQWWXPRUFHOOOLQHVKDVEHHQSUHYLRXVO\REVHUYHG21). Blocking integrin ơ1 inhibited cell-matrix interactions in HCV29 and BC3726 
cell lines, whereas binding of the bladder cancer cell lines 
T24 and Hu456 was enhanced (21). Each cell line therefore 
may possess a characteristic receptor set and long-term treat-PHQWZLWKFKHPRWKHUDS\PD\LQÁXHQFHLQWHJULQVXEIDPLOLHV
differently. Therefore systematic analysis of cell line panels is 
fundamental (6).:H GLG QRW LQYHVWLJDWH WKH UHOHYDQFH RI HDFK LQWHJULQPHPEHULQGHWDLOWKDWZDVXVHGKHUH7RSURYLGHDFRPSOHWH
picture of the role of integrin subtypes in gemcitabine- and 
cisplatin-resistant bladder cancer ongoing studies are neces-
sary. Particularly, blocking experiments using integrins Ơ3, Ơ5, and ơZRXOGEHRILQWHUHVW,QDGGLWLRQWKHVHÀQGLQJVDUH
limited to bladder cancer cell lines and bladder tissue. The role 
of integrins in chemoresistant bladder cancer should be further HYDOXDWHGin vivo in an animal model.2YHUDOOHYLGHQFHLVSUHVHQWHGKHUHWKDWDFTXLUHGUHVLVWDQFH
to gemcitabine or cisplatin frequently enhances chemotaxis, ZKDWPLJKWEHDVXUURJDWHIRUDQLQFUHDVHGLQYDVLYHEHKDYLRULQFKHPRUHVLVWDQWEODGGHUFDQFHUFHOOOLQHV6LQFHRYHUH[SUHV-
sion of integrin ơ1 seems to be frequently upregulated in 
chemoresistant urothelial bladder cancer cell lines, further 
in vivoVWXGLHVVKRXOGHYDOXDWHGRZQUHJXODWLRQRILQWHJULQơ1 
as a potential therapeutic target especially in chemotherapy 
refractory cases.
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